BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramos MJ, Bandiera L, Menolascina F, Fallowfield JA. In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications. iScience 2022;25:103549. [PMID: 34977507 DOI: 10.1016/j.isci.2021.103549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Gulzar F, Ahmad S, Singh S, Kumar P, Sharma A, Tamrakar AK. NOD1 activation in 3T3-L1 adipocytes confers lipid accumulation in HepG2 cells. Life Sci 2023;316:121400. [PMID: 36657640 DOI: 10.1016/j.lfs.2023.121400] [Reference Citation Analysis]
2 Guagliano G, Volpini C, Sardelli L, Bloise N, Briatico-Vangosa F, Cornaglia AI, Dotti S, Villa R, Visai L, Petrini P. Hep3Gel: A Shape-Shifting Extracellular Matrix-Based, Three-Dimensional Liver Model Adaptable to Different Culture Systems. ACS Biomater Sci Eng 2023;9:211-29. [PMID: 36525369 DOI: 10.1021/acsbiomaterials.2c01226] [Reference Citation Analysis]
3 Frohlich J, Raffaele M, Skalova H, Leire E, Pata I, Pata P, Gorbunova V, Vinciguerra M. Human centenarian–associated SIRT6 mutants modulate hepatocyte metabolism and collagen deposition in multilineage hepatic 3D spheroids. GeroScience 2022. [DOI: 10.1007/s11357-022-00713-1] [Reference Citation Analysis]
4 Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, Malek NP, Anstee QM, Heikenwalder M. A researcher's guide to preclinical mouse NASH models. Nat Metab 2022;4:1632-49. [PMID: 36539621 DOI: 10.1038/s42255-022-00700-y] [Reference Citation Analysis]
5 Khairnar R, Islam MA, Fleishman J, Kumar S. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sci 2022;312:121185. [PMID: 36375569 DOI: 10.1016/j.lfs.2022.121185] [Reference Citation Analysis]
6 Petkevicius K, Palmgren H, Glover MS, Ahnmark A, Andréasson AC, Madeyski-Bengtson K, Kawana H, Allman EL, Kaper D, Uhrbom M, Andersson L, Aasehaug L, Forsström J, Wallin S, Ahlstedt I, Leke R, Karlsson D, González-King H, Löfgren L, Nilsson R, Pellegrini G, Kono N, Aoki J, Hess S, Sienski G, Pilon M, Bohlooly-Y M, Maresca M, Peng XR. TLCD1 and TLCD2 regulate cellular phosphatidylethanolamine composition and promote the progression of non-alcoholic steatohepatitis. Nat Commun 2022;13:6020. [PMID: 36241646 DOI: 10.1038/s41467-022-33735-6] [Reference Citation Analysis]
7 Hu W, Lazar MA. Modelling metabolic diseases and drug response using stem cells and organoids. Nat Rev Endocrinol 2022. [PMID: 36071283 DOI: 10.1038/s41574-022-00733-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lee J, Mun SJ, Shin Y, Lee S, Son MJ. Advances in liver organoids: model systems for liver disease. Arch Pharm Res . [DOI: 10.1007/s12272-022-01390-6] [Reference Citation Analysis]
9 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]